News
Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...
Investor's Business Daily on MSN46m
The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback